Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Francesco Merli, Stefano Luminari, Fiorella Ilariucci, Mario Petrini, Carlo Visco, Achille Ambrosetti, Caterina Stelitano, Francesco Caracciolo, Nicola di Renzo, Francesco Angrilli, Angelo M. Carella, Isabella Capodanno, Elisa Barbolini, Sara Galimberti, Massimo Federico

Research output: Contribution to journalArticle

Abstract

This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine and methotrexate (AM)] in patients with newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70years with confirmed MCL received four alternating cycles each of R-HCVAD and AM. Patients who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three patients were enrolled and 60 were fully eligible. Median age was 57years (22-66); 60%, 33% and 7% were classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according to the MCL International Prognostic Index (MIPI). Only 22 patients (37%) completed the four cycles and three patients died during therapy. Overall response and complete response rates were 83% and 72% respectively. After a median follow-up of 46months (range 1-72) the estimated 5-year overall survival (OS) and progression-free survival rates were 73% [95% confidence interval (CI) 59-83%], and 61% (95%CI 45-73%) respectively. MIPI maintained the prognostic value with an estimated 5-year OS of 89%, 80% and 24% for L, I, and H groups respectively (P

Original languageEnglish
Pages (from-to)346-353
Number of pages8
JournalBritish Journal of Haematology
Volume156
Issue number3
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Chemotherapy
  • Clinical trials
  • Monoclonal antibodies
  • Non-Hodgkin lymphoma
  • Prognostic factors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi'. Together they form a unique fingerprint.

  • Cite this